Literature DB >> 11359787

Positioning the 3'-DNA terminus for topoisomerase II-mediated religation.

A M Wilstermann1, N Osheroff.   

Abstract

Despite the importance of the topoisomerase II DNA cleavage/rejoining cycle to genomic integrity, the mechanistic details of religation are poorly understood. Topoisomerase II utilizes covalent protein-DNA interactions to align the 5'-termini of cleaved DNA for religation. However, because the enzyme does not form covalent bonds with the 3'-DNA termini, the basis for the alignment of the 3'-ends is less clear. Three major possibilities exist. The 3'-termini may be positioned for religation (i) by base pairing to their complementary DNA strands, (ii) by base stacking to the adjacent residues, or (iii) by noncovalent interactions with topoisomerase II. To distinguish between these possibilities, the ability of human topoisomerase IIalpha to religate a series of oligonucleotides with altered base pairing or base stacking at their 3'-termini was determined. Substrates containing modifications that disrupted terminal base pairing or base stacking with-out affecting the 3'-terminal base were resealed at wild-type rates. In contrast, substrates that lacked the terminal base (or contained an altered base) displayed very low rates of religation. On the basis of these results, we propose that topoisomerase II positions the 3'-DNA termini for religation through noncovalent protein-DNA contacts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11359787     DOI: 10.1074/jbc.M100197200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  The alpha4 residues of human DNA topoisomerase IIalpha function in enzymatic activity and anticancer drug sensitivity.

Authors:  Namiko Suda; Yasutomo Ito; Tsuneo Imai; Toyone Kikumori; Akihiko Kikuchi; Yukihiro Nishiyama; Shonen Yoshida; Motoshi Suzuki
Journal:  Nucleic Acids Res       Date:  2004-03-16       Impact factor: 16.971

2.  Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer.

Authors:  Etchison Ryan; A Jacobson Blake; A Benoit; M Ferguson David; A Kratzke Robert
Journal:  Invest New Drugs       Date:  2012-07-22       Impact factor: 3.850

Review 3.  The use of divalent metal ions by type II topoisomerases.

Authors:  Joseph E Deweese; Neil Osheroff
Journal:  Metallomics       Date:  2010-05-21       Impact factor: 4.526

Review 4.  DNA topoisomerase II, genotoxicity, and cancer.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Mutat Res       Date:  2007-07-03       Impact factor: 2.433

5.  Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalpha.

Authors:  Joseph E Deweese; Alex B Burgin; Neil Osheroff
Journal:  Biochemistry       Date:  2008-03-05       Impact factor: 3.162

Review 6.  The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing.

Authors:  Joseph E Deweese; Neil Osheroff
Journal:  Nucleic Acids Res       Date:  2008-11-28       Impact factor: 16.971

7.  DNA-AP sites generation by etoposide in whole blood cells.

Authors:  Emilio Rojas; Patricia Mussali; Efrain Tovar; Mahara Valverde
Journal:  BMC Cancer       Date:  2009-11-16       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.